Jeffrey Sherman

Executive Vice President, Research and Development and Chief Medical Officer

 

Dr. Sherman joined Horizon Pharma in June 2009 as our executive vice president, development and regulatory affairs and chief medical officer. From June 2011 to September 2014, Dr. Sherman served as our executive vice president, development, manufacturing, and regulatory affairs, and chief medical officer. Since September 2014, Dr. Sherman has served as our executive vice president, research and development and chief medical officer.

From June 2009 through June 2010, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman is a former president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI) a public-private partnership founded by the US Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine.

From August 2007 through June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 through August 2007, he served as vice president of clinical science at Takeda Global Research and Development. From September 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company.

From October 1992 through August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle, a pharmaceutical company. Prior to joining Searle, Dr. Sherman worked in clinical pharmacology and clinical research at Bristol-Myers Squibb Company, a biopharmaceutical company. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.